Coloplast A/S – Interim Financial Report, Q1 2025/26
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast…
New employee representative on the Board of Directors of Novo Nordisk A/S
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board…
Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them
Company announcement no. 32 In accordance with Article 19 (3) of the…
Coloplast A/S – Announcement no. 07/2025 – Coloplast announces new financial ambition towards 2030
In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company…
Novo Nordisk A/S: Wegovy approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US…
NTG Nordic Transport Group A/S – H1 2025 Conference Call
July 14, 2025 02:00 ET | Source: NTG Nordic Transport Group A/S…
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
